TALENTOP

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Dec 10, 2020 → Oct 10, 2026

Cited window

Oct 23, 2021 → Oct 10, 2026

Retrieved

Oct 31, 2026

Title

A Multicenter, Randomized, Open-label Study Evaluating the Efficacy and Safety of Hepatic Resection for Hepatocellular Carcinoma With Venous Thrombosis After Initial Atezolizumab Plus Bevacizumab Treatment

Registry

NCT04649489

Study IDs

ML42435

Sponsor

Jia Fan

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

501 estimated

Registered

2020-12-02

Start

2021-04-19 actual

Primary completion

2027-08-31 estimated

Primary endpoint

TTF

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a view on continued systemic treatment burdens when conversion surgery is not indicated or tolerated.
• –Not yet captured in this edition: a view on conversion-treatment alternatives to resection, followed by consolidation and possible treatment cessation.
• –Not yet captured in this edition: a view on short follow-up, tentative recurrence-free survival extrapolation, and randomized confirmation of benefit from conversion surgery.
• –Not yet captured in this edition: a view on postoperative recurrence-free survival versus response duration as a proposed benchmark for surgery or continued systemic treatment.
• –Not yet captured in this edition: a view on benefits and risks of conversion surgery versus maintenance therapy for hepatocellular carcinoma with vascular invasion.
• –Not yet captured in this edition: a view on whether increasingly tolerable systemic treatment limits the additional quality-of-life benefit of conversion resection.
• –Not yet captured in this edition: a view on the safety trade-offs of conversion surgery versus maintenance systemic therapy after initial treatment.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –30 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –This report describes the sources reviewed for this edition, not all HCP discussion or a representative sample of clinical opinion.
• –Parts of the early conversion-treatment discussion remain incompletely represented, including treatment-stopping burdens, nonoperative local options and comparisons of benefit duration.
• –Repeated posts, reposts, relayed presentations and organizational accounts cannot be treated as independent clinician endorsements or used to estimate consensus.
• –The identity of speakers in the 2021 conversion-treatment presentation and the POST ESMO 2025 episode is not established for the statements used here.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Differences in endpoint labels, safety percentages, denominators and emphatic survival interpretations remain attributed to their authors rather than reconciled into a single clinical result.
• –Historical patient experiences and preliminary conversion-treatment observations are not TALENTOP comparative outcomes.
• –No separate protocol document or exact combination-product label was available; the registry and published results provide the primary study context.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "TALENTOP" (NCT04649489), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "talentop-04649489". If you cannot make requests, read https://www.erudio.com/reports/talentop-nct04649489.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT04649489", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct04649489 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/talentop-nct04649489.json
curl https://www.erudio.com/reports/talentop-nct04649489.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "talentop-04649489" })